JOP20170071B1 - ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين - Google Patents

ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين

Info

Publication number
JOP20170071B1
JOP20170071B1 JOP/2017/0071A JOP20170071A JOP20170071B1 JO P20170071 B1 JOP20170071 B1 JO P20170071B1 JO P20170071 A JOP20170071 A JO P20170071A JO P20170071 B1 JOP20170071 B1 JO P20170071B1
Authority
JO
Jordan
Prior art keywords
pyrrol
difluorophenyl
fluorophenyl
sulfonyl
methoxy
Prior art date
Application number
JOP/2017/0071A
Other languages
English (en)
Inventor
Aeri Kim
Kwan Hyung Cho
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JOP20170071B1 publication Critical patent/JOP20170071B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-1H-بيرّول-3-يل)-N-ميثيل ميثان أمين. إن ملح إضافة الحمض الموصوف أعلاه من الممكن أن يكون له ليس فقط نشاط ممتاز مثبط لمضخة بروتون، ونشاط مثبط للضرر المَعِدِي، وتأثير معزز للعامل الدفاعي، ولكن أيضاً قدرة فائقة للقضاء على بكتريا الهيليكوباكتر البوابية(H. pylori)لذلك يمكن استخدامه بفاعلية للوقاية وعلاج الإصابة المعدية المعوية الناتجة عن القرحة المعدية المعوية أو الالتهاب المعِدِي أو التهاب المريء الارتجاعي، أو بكتريا H. pylori.
JOP/2017/0071A 2016-03-25 2017-03-22 ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين JOP20170071B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160036081 2016-03-25
KR1020170018336A KR20170113040A (ko) 2016-03-25 2017-02-09 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염

Publications (1)

Publication Number Publication Date
JOP20170071B1 true JOP20170071B1 (ar) 2021-08-17

Family

ID=60141235

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0071A JOP20170071B1 (ar) 2016-03-25 2017-03-22 ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين

Country Status (28)

Country Link
US (1) US10487053B2 (ar)
EP (1) EP3433232B1 (ar)
JP (1) JP6609065B2 (ar)
KR (2) KR20170113040A (ar)
CN (1) CN108602771B (ar)
AR (1) AR107964A1 (ar)
AU (1) AU2017238917B2 (ar)
CA (1) CA3014753C (ar)
CL (1) CL2018002415A1 (ar)
CO (1) CO2018008834A2 (ar)
DO (2) DOP2018000191A (ar)
ES (1) ES2811478T3 (ar)
HR (1) HRP20201571T1 (ar)
HU (1) HUE053741T2 (ar)
JO (1) JOP20170071B1 (ar)
MA (1) MA43832B1 (ar)
MX (1) MX379775B (ar)
MY (1) MY196355A (ar)
NZ (1) NZ745267A (ar)
PE (1) PE20190169A1 (ar)
PH (1) PH12018501845B1 (ar)
PL (1) PL3433232T3 (ar)
PT (1) PT3433232T (ar)
RS (1) RS60857B1 (ar)
SG (1) SG11201806968RA (ar)
SI (1) SI3433232T1 (ar)
TN (1) TN2018000269A1 (ar)
TW (1) TWI607753B (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
KR102570011B1 (ko) * 2019-12-18 2023-08-23 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루우로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물
CN115884968B (zh) * 2020-06-17 2024-06-21 日东制药株式会社 新型酸分泌抑制剂及其用途
DK4245298T3 (en) * 2020-12-18 2026-03-30 Daewoong Pharmaceutical Co Ltd Hidtil ukendt formulering til oral administration, som omfatter 1-(5-(2,4-difluorphenyl)-1-((3-fluorphenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamin
JP7802829B2 (ja) * 2021-05-26 2026-01-20 デウン ファーマシューティカル カンパニー リミテッド １－（５－（２，４－ジフルオロフェニル）－１－（（３－フルオロフェニル）スルホニル）－４－メトキシ－１ｈ－ピロール－３－イル）－ｎ－メチルメタンアミンを含む新規な注射用製剤
TN2023000270A1 (en) * 2021-05-26 2025-07-02 Daewoong Pharmaceutical Co Ltd Medicine container containing liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
TW202304426A (zh) * 2021-05-26 2023-02-01 南韓商大熊製藥股份有限公司 用於注射之包含１－（５－（２，４－二氟苯基）－１－（（３－氟苯基）磺醯基）－４－甲氧基－１ｈ－吡咯－３－基）－ｎ－甲基甲胺的新調配物
US20240415808A1 (en) * 2021-12-15 2024-12-19 Daewoong Pharmaceutical Co., Ltd. Dosage Regimen for Fexuprazan Injection Composition
CN118401510A (zh) * 2021-12-15 2024-07-26 日东制药株式会社 1-磺酰基吡咯衍生物的新颖盐类、其制备方法及包含其的药物组合物
KR20240119083A (ko) * 2021-12-15 2024-08-06 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
WO2023229323A1 (ko) * 2022-05-23 2023-11-30 일동제약(주) 6-메톡시피리딘-3-일 유도체의 제조방법
CN119365448A (zh) * 2022-05-23 2025-01-24 日东制药株式会社 一种6-甲氧基吡啶-3-基衍生物的制备方法
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法
KR102938657B1 (ko) * 2023-02-15 2026-03-12 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101178747B1 (ko) 2004-09-30 2012-09-03 다케다 야쿠힌 고교 가부시키가이샤 프로톤 펌프 저해제
PE20070540A1 (es) 2005-08-30 2007-06-26 Takeda Pharmaceutical Derivados de pirrol como inhibidores de la secrecion acida
WO2007114338A1 (ja) * 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
WO2008036211A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
CA2891523A1 (en) * 2012-11-19 2014-05-22 Jiangsu Hansoh Pharmaceutical Co., Ltd. Pyrrole sulfonamide derivative, preparation method for same, and medical application thereof
WO2014133059A1 (ja) * 2013-02-28 2014-09-04 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
TN2018000269A1 (en) 2020-01-16
PH12018501845B1 (en) 2022-02-18
EP3433232B1 (en) 2020-07-15
MX2018009220A (es) 2018-09-10
SI3433232T1 (sl) 2020-10-30
JP6609065B2 (ja) 2019-11-20
HK1254394A1 (zh) 2019-07-19
HRP20201571T1 (hr) 2020-12-11
NZ745267A (en) 2020-03-27
US10487053B2 (en) 2019-11-26
ES2811478T3 (es) 2021-03-12
KR20170113040A (ko) 2017-10-12
MY196355A (en) 2023-03-24
MX379775B (es) 2025-03-11
CN108602771B (zh) 2021-07-16
CA3014753A1 (en) 2017-09-28
DOP2018000191A (es) 2018-09-30
KR102417830B1 (ko) 2022-07-06
AU2017238917A1 (en) 2018-08-16
TW201737908A (zh) 2017-11-01
BR112018069540A2 (pt) 2019-01-29
AU2017238917B2 (en) 2019-07-11
US20190031609A1 (en) 2019-01-31
JP2019509320A (ja) 2019-04-04
MA43832B1 (fr) 2020-08-31
DOP2021000001A (es) 2021-03-15
CL2018002415A1 (es) 2018-12-28
PL3433232T3 (pl) 2020-12-14
KR20200105771A (ko) 2020-09-09
PH12018501845A1 (en) 2019-05-15
PT3433232T (pt) 2020-07-21
HUE053741T2 (hu) 2021-07-28
SG11201806968RA (en) 2018-09-27
RS60857B1 (sr) 2020-10-30
CA3014753C (en) 2023-08-29
PE20190169A1 (es) 2019-02-01
TWI607753B (zh) 2017-12-11
CN108602771A (zh) 2018-09-28
EP3433232A1 (en) 2019-01-30
EP3433232A4 (en) 2019-07-31
AR107964A1 (es) 2018-07-04
CO2018008834A2 (es) 2018-10-10

Similar Documents

Publication Publication Date Title
JOP20170071B1 (ar) ملح إضافة حمض جديد من 1-(5-(2، 4-داي فلورو فينيل)-1-((3-فلورو فينيل)سلفونيل)-4-ميثوكسي-h1-بيرّول-3-يل)-n-ميثيل ميثان أمين
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
MY193257A (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
EA201790271A1 (ru) Ингибиторы гликозидазы
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
EA201790453A2 (ru) Новая соль присоединения кислоты 1-(5-(2,4-дифторфенил)-1-((3- фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
EA201990279A1 (ru) Гербицидные композиции, содержащие фенилпиримидины
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
PE20190170A1 (es) Nueva forma cristalina de sal de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
TH1801004904A (th) เกลือเพิ่มกรดแบบใหม่ของ 1-(5-(2,4-ไดฟลูออโรฟีนิล)-1-((3-ฟลูออโรฟีนิล)ซัลโฟนิล)-4-มีท็อกซี-1h-ไพร์โรล-3-อิล)-n-เมทิลมีเทนอะมีน
AR108995A1 (es) 4-alcoxi-3-(acil o alquil)oxipicolinamidas e intermediarios para su preparación
EA202090357A1 (ru) Химические соединения
MA38479B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante